DuPont/Nova
Executive Summary
DuPont Medical Products signs five-year agreement with receptor R&D firm Nova Pharmaceutical covering development and marketing of products for the molecular screening of chemical compounds for biological activity. Using its NovaScreen technology, Nova will develop and test products for DuPont, which will receive manufacturing and marketing rights. The first products will be kits for performing receptor binding assays. Nova also has drug screening pacts with Sterling and NIH as well as with several Japanese firms.
You may also be interested in...
Interview: Theradaptive To Enter Clinical Trial For Spinal Fusion Gel
Theradaptive, which makes a device-biologic combination product to help speed bone healing, recently got authorization to start human trials from the US FDA. Medtech Insight spoke to CEO Luis Alvarez about the company’s past, present and future.
US FDA Expects Joint AdComm Briefing Document, Oncology Chief Says
The combined format is the new default for briefing advisory committee members, US FDA Oncology Center of Excellence Director Pazdur declared.
Parallel Scientific Advice: Is The EMA User Fee Impacting Interest?
EMA charges participants to receive scientific advice through the fledgling program, unlike the US FDA, which may not fit the budgets of some complex generic sponsors. At the same time, sponsors also may simply not be aware the program exists yet.